BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 15831697)

  • 1. Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance.
    Alcalay M; Tiacci E; Bergomas R; Bigerna B; Venturini E; Minardi SP; Meani N; Diverio D; Bernard L; Tizzoni L; Volorio S; Luzi L; Colombo E; Lo Coco F; Mecucci C; Falini B; Pelicci PG
    Blood; 2005 Aug; 106(3):899-902. PubMed ID: 15831697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin.
    Garzon R; Garofalo M; Martelli MP; Briesewitz R; Wang L; Fernandez-Cymering C; Volinia S; Liu CG; Schnittger S; Haferlach T; Liso A; Diverio D; Mancini M; Meloni G; Foa R; Martelli MF; Mecucci C; Croce CM; Falini B
    Proc Natl Acad Sci U S A; 2008 Mar; 105(10):3945-50. PubMed ID: 18308931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features.
    Falini B; Nicoletti I; Martelli MF; Mecucci C
    Blood; 2007 Feb; 109(3):874-85. PubMed ID: 17008539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity.
    Rau R; Brown P
    Hematol Oncol; 2009 Dec; 27(4):171-81. PubMed ID: 19569254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia.
    Falini B; Mecucci C; Saglio G; Lo Coco F; Diverio D; Brown P; Pane F; Mancini M; Martelli MP; Pileri S; Haferlach T; Haferlach C; Schnittger S
    Haematologica; 2008 Mar; 93(3):439-42. PubMed ID: 18268276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
    Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
    Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin.
    Quentmeier H; Martelli MP; Dirks WG; Bolli N; Liso A; Macleod RA; Nicoletti I; Mannucci R; Pucciarini A; Bigerna B; Martelli MF; Mecucci C; Drexler HG; Falini B
    Leukemia; 2005 Oct; 19(10):1760-7. PubMed ID: 16079892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias.
    Falini B; Nicoletti I; Bolli N; Martelli MP; Liso A; Gorello P; Mandelli F; Mecucci C; Martelli MF
    Haematologica; 2007 Apr; 92(4):519-32. PubMed ID: 17488663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: Impact on WHO classification.
    Pasqualucci L; Liso A; Martelli MP; Bolli N; Pacini R; Tabarrini A; Carini M; Bigerna B; Pucciarini A; Mannucci R; Nicoletti I; Tiacci E; Meloni G; Specchia G; Cantore N; Di Raimondo F; Pileri S; Mecucci C; Mandelli F; Martelli MF; Falini B
    Blood; 2006 Dec; 108(13):4146-55. PubMed ID: 16926285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The incidence and clinical significance of nucleophosmin mutations in childhood AML.
    Brown P; McIntyre E; Rau R; Meshinchi S; Lacayo N; Dahl G; Alonzo TA; Chang M; Arceci RJ; Small D
    Blood; 2007 Aug; 110(3):979-85. PubMed ID: 17440048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of the cytoplasmic NPM1 mutant (NPMc+) causes the expansion of hematopoietic cells in zebrafish.
    Bolli N; Payne EM; Grabher C; Lee JS; Johnston AB; Falini B; Kanki JP; Look AT
    Blood; 2010 Apr; 115(16):3329-40. PubMed ID: 20197555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immunohistochemical demonstration of mutant nucleophosmin in acute myeloid leukemia: biological and clinical features related to NPMc expression].
    Bedekovics J; Rejto L; Telek B; Udvardy M; Ujfalusi A; Oláh E; Hevessy Z; Kappelmayer J; Kajtár B; Méhes G
    Orv Hetil; 2009 May; 150(22):1031-5. PubMed ID: 19465351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meis1 programs transcription of FLT3 and cancer stem cell character, using a mechanism that requires interaction with Pbx and a novel function of the Meis1 C-terminus.
    Wang GG; Pasillas MP; Kamps MP
    Blood; 2005 Jul; 106(1):254-64. PubMed ID: 15755900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia.
    Noguera NI; Ammatuna E; Zangrilli D; Lavorgna S; Divona M; Buccisano F; Amadori S; Mecucci C; Falini B; Lo-Coco F
    Leukemia; 2005 Aug; 19(8):1479-82. PubMed ID: 15973451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations.
    Mizuki M; Schwable J; Steur C; Choudhary C; Agrawal S; Sargin B; Steffen B; Matsumura I; Kanakura Y; Böhmer FD; Müller-Tidow C; Berdel WE; Serve H
    Blood; 2003 Apr; 101(8):3164-73. PubMed ID: 12468433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.
    Falini B; Mecucci C; Tiacci E; Alcalay M; Rosati R; Pasqualucci L; La Starza R; Diverio D; Colombo E; Santucci A; Bigerna B; Pacini R; Pucciarini A; Liso A; Vignetti M; Fazi P; Meani N; Pettirossi V; Saglio G; Mandelli F; Lo-Coco F; Pelicci PG; Martelli MF;
    N Engl J Med; 2005 Jan; 352(3):254-66. PubMed ID: 15659725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delocalization and destabilization of the Arf tumor suppressor by the leukemia-associated NPM mutant.
    Colombo E; Martinelli P; Zamponi R; Shing DC; Bonetti P; Luzi L; Volorio S; Bernard L; Pruneri G; Alcalay M; Pelicci PG
    Cancer Res; 2006 Mar; 66(6):3044-50. PubMed ID: 16540653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patients.
    Andersson A; Johansson B; Lassen C; Mitelman F; Billström R; Fioretos T
    Eur J Haematol; 2004 May; 72(5):307-13. PubMed ID: 15059064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice.
    Falini B; Martelli MP; Mecucci C; Liso A; Bolli N; Bigerna B; Pucciarini A; Pileri S; Meloni G; Martelli MF; Haferlach T; Schnittger S
    Haematologica; 2008 May; 93(5):775-9. PubMed ID: 18367491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hox expression in AML identifies a distinct subset of patients with intermediate cytogenetics.
    Roche J; Zeng C; Barón A; Gadgil S; Gemmill RM; Tigaud I; Thomas X; Drabkin HA
    Leukemia; 2004 Jun; 18(6):1059-63. PubMed ID: 15085154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.